-

Schrödinger to Announce Third Quarter 2025 Financial Results on November 5

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.

The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event.

About Schrödinger
Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger’s software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.

Contacts

Matthew Luchini (Investors)
Schrödinger, Inc.
matthew.luchini@schrodinger.com
917-719-0636

Allie Nicodemo (Media)
Schrödinger, Inc.
allie.nicodemo@schrodinger.com
617-356-2325

Industry:

Schrödinger

NASDAQ:SDGR
Release Versions
English

Contacts

Matthew Luchini (Investors)
Schrödinger, Inc.
matthew.luchini@schrodinger.com
917-719-0636

Allie Nicodemo (Media)
Schrödinger, Inc.
allie.nicodemo@schrodinger.com
617-356-2325

Social Media Profiles
Schrödinger Instagram
Schrödinger LinkedIn
More News From Schrödinger

Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2025, and provided its 2026 outlook and 2028 financial objectives. "Schrödinger’s performance in 2025, marked by 23% total revenue growth and 11% software revenue growth, is a testament to the resilience of our business and the unique value we provide," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. “While the drug discovery AI la...

Schrödinger to Participate in Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in the following conferences in March: TD Cowen 46th Annual Health Care Conference: Fireside chat on Tuesday, March 3, 2026 at 9:50 a.m. E.T. Leerink Global Healthcare Conference 2026: Fireside chat on Tuesday, March 10, 2026 at 1:40 p.m. E.T. KBCM Healthcare Forum: Fireside chat on Tuesday, March 17, 2026 at 9:00 a.m. E.T. The live discussions can be accessed in the “Investors” section...

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on February 13, 2026, the company granted (i) non-statutory stock options to purchase 9,600 shares of the company’s common stock to two newly hired employees and (ii) restricted stock units (RSUs) with respect to 18,250 shares of the company’s common stock to eight newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committe...
Back to Newsroom